SCHEMBL3745658

SCHEMBL3745658

CN(Cc1ccccc1)C(=O)C1c2ccccc2C(=O)N1CCc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
MDM2 Q00987 4/20 0.46
HTT P42858 2/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 2/20 0.41
P2RX7 Q99572 3/20 0.41
TP53 P04637 1/20 0.41
KCNA5 P22460 2/20 0.41
KCNH2 Q12809 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758475 0.92 MDM2 (0.46) MDM2HTTALDH1A1P2RX7TP53
SCHEMBL3751140 0.88 MDM2 (0.44) MDM2HTTALDH1A1P2RX7TP53
SCHEMBL3748832 0.86 KCNA5 (0.46) MDM2ALDH1A1P2RX7TP53KCNA5
SCHEMBL3751721 0.85 P2RX7 (0.47) PRMT5WDR77MDM2P2RX7KCNA5
SCHEMBL3754163 0.84 KCNA5 (0.44) MDM2HTTALDH1A1KCNA5KCNH2
SCHEMBL3762651 0.84 MDM2 (0.46) MDM2P2RX7TP53KCNA5KCNH2
SCHEMBL3750835 0.83 MDM2 (0.57) MDM2HTTALDH1A1P2RX7TP53
SCHEMBL3750322 0.82 MDM2 (0.40) MDM2HTTALDH1A1P2RX7TP53
SCHEMBL3753733 0.81 ALDH1A1 (0.62) MDM2SMN1; SMN2ALDH1A1P2RX7TP53
SCHEMBL3751622 0.79 SCN9A (0.62) P2RX7KCNA5KCNH2SCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 PRMT5 1341/4885WDR77 2402/4885MDM2 3686/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 PRMT5 683/4885WDR77 2954/4885MDM2 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.